MGLL and movement disorder: MAGL inhibitors have been developed for the therapeutic management of pain, movement disorders, and neurodegenerative diseases, involving mechanisms such as stimulating 2-AG production or limiting the expression of PGE2 and pro-inflammatory cytokines [11, 13, 44–46].